〔Abstract〕 Objective To explore the effect of apatini united SOX solution chemotherapy for patients with advanced gastric cancer. Methods A retrospective study was performed on 83 patients with advanced gastric cancer admitted to Henan Military Hospital from July 2017 to June 2019. 44 patients received apatinib combined with SOX regimen as the observation group, and 39 patients received SOX regimen as the control group. The therapeutic effect, serum vascular endothelial growth factor (VEGF) levels and gastric cancer quality of life scale (QLQ -- STO 22) before and after treatment were compared between the two groups. Results The objective remission rate of observation group was 84.09 %, higher than 58.97 % of control group, the difference was statistically significant (P < 0.05). There was no significant difference in VEGF level and QLQ-STO 22 score between the two groups before treatment (P > 0.05). After treatment, VEGF level and QLQ-STO 22 score in two groups were decreased to varying degrees, and the observation group was lower than the control group, the difference was statistically significant (P < 0.05). Conclusion Apatinib combined with SOX chemotherapy is effective in the treatment of advanced gastric cancer patients, which can significantly reduce serum VEGF level and improve the quality of life.